Reed Jobs would rather talk about curing cancer than his last name
- ID
- 4210
- Status
- summarized
- Published
- 12 Jul 2026, 8:16 AM
- Fetched
- 13 Jul 2026, 9:51 PM
- Provider
- TechCrunch
- Category
- technology
- Original URL
- https://techcrunch.com/2026/07/11/reed-jobs-would-rather-talk-about-curing-cancer-than-his-last-name/
- Source URL
- https://techcrunch.com/feed/
Summary
- Score
- 5.5
- Created
- 13 Jul 2026, 9:51 PM
- Tags
- Audience
- saas_foundersai_ml_learners
What happened
Reed Jobs' venture firm Yosemite has grown to a team of 17 and now treats AI as a core part of its biotech investment approach, partly driven by a wave of blockbuster drugs losing patent protection. Jobs says the firm is moving faster than he expected, with AI shifting from a curiosity to a central tool in how Yosemite operates.
Why it matters
For SaaS/startup founders and AI/ML learners, this is a signal that AI is becoming operational infrastructure in biotech investing, not just a buzzword. Malaysian builders in healthtech or deep-tech can note the patent cliff angle as a window for new entrants, and the broader lesson that AI adoption in specialized verticals is accelerating faster than incumbents expected.
Discussion angle
How the patent cliff in pharma creates openings for AI-driven startups and funds, and whether similar 'cliff' dynamics exist in other regulated industries relevant to Malaysian builders.